Analysts Set $110.00 Price Target for Taro Pharmaceutical Industries Ltd. (NYSE:TARO)
Shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Brokerages have set a 12 month consensus price objective of $110.00 for the company and are expecting that the company will post $1.54 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Taro Pharmaceutical Industries an industry rank of 65 out of 255 based on the ratings given to related companies.
TARO has been the topic of a number of research analyst reports. ValuEngine raised Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Zacks Investment Research cut Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a report on Friday, November 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $110.00 price objective (up from $105.00) on shares of Taro Pharmaceutical Industries in a research report on Tuesday, November 5th.
Taro Pharmaceutical Industries (NYSE:TARO) last posted its earnings results on Monday, November 4th. The company reported $1.46 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.72 by ($0.26). Taro Pharmaceutical Industries had a return on equity of 14.13% and a net margin of 40.43%. The business had revenue of $160.85 million for the quarter, compared to the consensus estimate of $168.60 million. Equities analysts forecast that Taro Pharmaceutical Industries will post 6.45 earnings per share for the current year.
Several hedge funds have recently modified their holdings of the company. Commonwealth Bank of Australia increased its holdings in shares of Taro Pharmaceutical Industries by 62.5% during the second quarter. Commonwealth Bank of Australia now owns 1,300 shares of the company’s stock valued at $111,000 after acquiring an additional 500 shares in the last quarter. Squarepoint Ops LLC raised its holdings in Taro Pharmaceutical Industries by 7.2% in the 3rd quarter. Squarepoint Ops LLC now owns 3,306 shares of the company’s stock worth $249,000 after purchasing an additional 222 shares during the period. Jane Street Group LLC purchased a new position in Taro Pharmaceutical Industries during the second quarter valued at $290,000. Tower Research Capital LLC TRC lifted its position in Taro Pharmaceutical Industries by 500.9% during the second quarter. Tower Research Capital LLC TRC now owns 3,810 shares of the company’s stock valued at $325,000 after purchasing an additional 3,176 shares in the last quarter. Finally, Trexquant Investment LP bought a new stake in Taro Pharmaceutical Industries during the second quarter valued at about $337,000. 10.54% of the stock is owned by institutional investors.
About Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
See Also: Why Dividend Stocks May Be Right for You
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.